Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 3
2015 1
2017 1
2018 2
2020 1
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, Boughan K, Hillian A, Reese-Koc J, Maschan M, Dropulic B, Sekaly RP, de Lima M. Caimi PF, et al. Among authors: reese koc j. Front Immunol. 2021 Oct 12;12:745320. doi: 10.3389/fimmu.2021.745320. eCollection 2021. Front Immunol. 2021. PMID: 34712233 Free PMC article.
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Otegbeye F, Cooper B, Caimi P, Zamborsky K, Reese-Koc J, Hillian A, Hernandez-Collazo Y, Lee G, Boughan K, Tomlinson B, Gallogly M, Metheny L, Bajor D, Selfridge J, Saltzman J, Lazarus H, de Lima M, Wald D. Otegbeye F, et al. Among authors: reese koc j. Transplant Cell Ther. 2022 May;28(5):250.e1-250.e8. doi: 10.1016/j.jtct.2022.02.008. Epub 2022 Feb 14. Transplant Cell Ther. 2022. PMID: 35172204 Free PMC article. Clinical Trial.
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.
Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, Shelikhova L, Pershin D, Stepanov A, Muzalevskii Y, Suzart VG, Otegbeye F, Wald D, Xiong Y, Wu D, Knight A, Oparaocha I, Ferencz B, Roy A, Worden A, Kruger W, Kadan M, Schneider D, Orentas R, Sekaly RP, de Lima M, Dropulić B. Maschan M, et al. Among authors: reese koc j. Nat Commun. 2021 Dec 10;12(1):7200. doi: 10.1038/s41467-021-27312-6. Nat Commun. 2021. PMID: 34893603 Free PMC article.
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM. Cohen JA, et al. Among authors: reese koc j. Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6. Mult Scler. 2018. PMID: 28381130 Free PMC article.
Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens.
Wang J, Sanati F, Firoozmand A, Fu P, Kolk M, Reese-Koc J, de Lima M, Boughan K, Cooper B, Caimi P, Gallogly M, Otegbeye F, Tomlinson B, Metheny L. Wang J, et al. Among authors: reese koc j. Front Oncol. 2023 May 3;13:1186532. doi: 10.3389/fonc.2023.1186532. eCollection 2023. Front Oncol. 2023. PMID: 37207167 Free PMC article.
Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria.
Ahmed N, Li L, Rojas P, Covut F, Reese-Koc J, Kolk M, Malek E, Metheny L, O'Brien T, Caimi P, de Lima M, Cooper BW. Ahmed N, et al. Among authors: reese koc j. Bone Marrow Transplant. 2021 Jun;56(6):1458-1461. doi: 10.1038/s41409-021-01223-y. Epub 2021 Jan 29. Bone Marrow Transplant. 2021. PMID: 33514923 Free PMC article. No abstract available.
17 results